Therapeutic targets in the ARF tumor suppressor pathway

Anthony J Saporita1, Leonard B Maggi, Anthony J Apicelli

  • 1Departments of Internal Medicine and Cell Biology, Division of Molecular Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110 USA.

Insights

The ARF tumor suppressor prevents uncontrolled cell growth by sensing oncogenic stress and stabilizing p53. This review explores ARF

Area of Science:

  • Cancer Cell Biology
  • Tumor Suppressor Mechanisms
  • Cell Cycle Regulation

Background:

  • Coordinating cellular growth with cell cycle progression is crucial for multicellular organisms.
  • Mammalian cells require sophisticated control mechanisms beyond nutrient availability to regulate growth.
  • Cell-autonomous surveillance against oncogenic stress is necessary to prevent uncontrolled proliferation.

Purpose of the Study:

  • To review the p53-dependent and independent functions of the ARF tumor suppressor.
  • To summarize models of ARF's role in controlling cell proliferation and macromolecular synthesis.
  • To discuss therapeutic targets within the ARF pathway for cancer treatment.

Main Methods:

  • Literature review of existing research on ARF and its related pathways.
  • Analysis of oncogenic stress induction of ARF expression.
  • Examination of ARF's interaction with p53 stabilization and cell cycle arrest.

Main Results:

  • ARF is potently induced by oncogenic stress (e.g., Ras, myc overexpression).
  • Induced ARF stabilizes the tumor suppressor protein p53, leading to cell cycle arrest.
  • Mutations in the INK4a/Arf locus are frequent in cancer, second only to p53 mutations.

Conclusions:

  • ARF acts as a critical sensor of oncogenic stress, preventing unwarranted cell growth.
  • ARF and p53 likely function coordinately to maintain genomic stability and suppress tumorigenesis.
  • Targeting the ARF pathway offers potential therapeutic strategies for cancer intervention.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...